Valuation: Viking Therapeutics, Inc.

Market Cap 3.51B 3.06B 2.88B 2.63B 4.92B 336B 4.93B 34.54B 13.31B 171B 13.19B 12.9B 553B P/E 2026 *
-6.53x
P/E 2027 * -7.09x
Enterprise Value 3.07B 2.68B 2.52B 2.3B 4.31B 294B 4.31B 30.22B 11.65B 150B 11.54B 11.29B 484B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day+3.86%
1 week-4.50%
Current month-8.15%
1 month-11.15%
3 months-0.89%
6 months-6.87%
Current year-14.41%
1 week 28.4
Extreme 28.4
30.77
1 month 28.4
Extreme 28.4
34.99
Current year 25.77
Extreme 25.77
42.79
1 year 24.78
Extreme 24.78
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 23/09/2012
Director of Finance/CFO 55 03/01/2021
Chief Tech/Sci/R&D Officer 57 10/06/2026
Director TitleAgeSince
Chairman 68 30/04/2015
Chairman 60 23/09/2012
Director/Board Member 53 30/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Free

Director

47,133 0.0404%
29/07/26 Sell

Chief Operating Officer

-18,217 0.0157%
29/07/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
+3.86%-4.50%+18.54%+126.22% 3.51B
+4.98%+5.73%+54.45%+113.83% 74.33B
-0.39%+0.02%+38.84%+83.28% 62.26B
0.00%+7.68%+32.24%+24.27% 27.72B
+0.83%-3.43%-16.41%+359.38% 26.42B
+2.02%-0.87%+1.85%-7.92% 24.62B
0.00%+6.81%+25.03%-11.44% 20.72B
-2.54%-3.36%+149.64%+324.48% 15.01B
-1.95%+1.80%+42.69%+165.15% 14.18B
-5.32%-8.25%-10.53%+823.50% 13.48B
Average +0.15%+0.28%+33.63%+200.07% 28.23B
Weighted average by Cap. +1.04%+2.21%+36.36%+149.30%

Financials

2026 *2027 *
Net sales - -
Net income -541M -472M -444M -405M -759M -51.85B -760M -5.32B -2.05B -26.41B -2.03B -1.99B -85.23B -539M -470M -443M -403M -756M -51.66B -757M -5.3B -2.04B -26.32B -2.03B -1.98B -84.92B
Net Debt -439M -383M -361M -329M -616M -42.09B -617M -4.32B -1.67B -21.44B -1.65B -1.61B -69.18B -520M -453M -427M -389M -729M -49.79B -730M -5.11B -1.97B -25.36B -1.95B -1.91B -81.85B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
21/09/26 US$30.11 +3.86% 5,086,724
18/09/26 US$28.99 -1.26% 2,671,391
17/09/26 US$29.36 -0.54% 2,086,755
16/09/26 US$29.52 -1.44% 3,009,486
15/09/26 US$29.95 -5.01% 2,807,988
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
30.11USD
Average target price
92.39USD
Spread / Average Target
+206.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!